What 'controlled resorption' actually means for your joint

A reasonable question surfaces early for most patients: if the scaffold eventually breaks down, what remains inside the joint? The answer is the point of the whole treatment — the scaffold is designed to disappear, but only once the body has used it as a template to build its own replacement tissue. Permanent is not the goal; a clean handover is.

Controlled resorption means the scaffold degrades at a pace deliberately matched to the rate at which migrating cells can lay down new cartilage matrix. That timing balance matters in both directions. If the scaffold breaks down too quickly, the structural template vanishes before the body has finished building, and the defect risks collapsing back toward scar-like fibrocartilage. If it lingers too long, the maturing cells cannot complete the transition from provisional scaffold to durable, collagen-rich native tissue. This is also what separates a regenerative scaffold from a lubricant or a filler: the aim is not to occupy space indefinitely, but to be replaced — precisely and progressively — by the patient's own cartilage.

What ChondroFiller is made of and how it sets inside the joint

ChondroFiller® is built from Type I collagen — the same structural protein that forms much of the body's native connective tissue, including healthy articular cartilage. Some descriptions of the product refer to a Type I/III collagen matrix composition, reflecting the fibrillar architecture of the scaffold. The collagen is derived from murine tissue and processed to remove all cellular material, leaving a purified extracellular matrix protein.

The product is supplied as a liquid. When placed into a cartilage defect — delivered under image guidance as an outpatient procedure for suitable cases — it undergoes in-situ polymerisation: warming to physiological temperature within the joint, it self-gels within minutes and conforms to the three-dimensional geometry of the defect. This liquid-to-gel transition removes the requirement to carve the defect cavity to a standardised shape before implantation, which is part of what makes image-guided injection feasible for appropriate patients.

Acellular means the scaffold carries no donor cells of any kind. It is a structural matrix only — a porous, fibrillar framework whose role is to provide the physical environment for the patient's own progenitor cells to migrate in from surrounding tissue. The biological activity that follows comes from the body; the scaffold supplies the architecture.

How the body breaks the scaffold down

Matrix metalloproteinases — MMPs — are remodelling enzymes produced naturally within the synovial environment. Their function is to break down and renew connective-tissue proteins, and Type I collagen is among their native substrates. ChondroFiller's scaffold is engineered with this in mind: rather than resisting the joint's own enzymatic machinery, the collagen matrix is designed to be degraded by it.

This physiological basis matters for tolerability. Because breakdown is enzyme-driven, it does not generate the acid metabolites or inflammatory by-products that can accompany the hydrolytic degradation of synthetic polymer scaffolds such as polylactic or polyglycolic acid. The joint processes the collagen fibres in much the same way it handles worn connective tissue — gradually and without mounting an immune response to a foreign chemical breakdown product.

The speed of that process is where material engineering enters. Scaffold porosity and fibre density are the primary variables that control how quickly MMPs can access and work through the matrix. A more open pore architecture allows faster enzymatic penetration; a denser network slows it. Calibrating this balance to the six-to-twelve-month regeneration window is what ties the material design to the clinical outcome.

The precise collagen concentration, crosslinking chemistry, and target MMP profile used in ChondroFiller's formulation are held proprietary and are not detailed in published literature, so while the degradation mechanism is well-characterised biologically, the exact formulation parameters are not in the public domain.

Why the timing window is so critical

A useful frame here is structural scaffolding on a building site. The scaffold needs to stay up long enough for the walls to develop their own load-bearing capacity — remove it too soon and the structure fails before it can stand alone. Leave it too long and the scaffold itself starts to obstruct the finishing work. The principle governing ChondroFiller's resorption window is the same.

The six-to-twelve-month regeneration period reported in published clinical series is not an arbitrary waiting time. It reflects deliberate calibration: the scaffold's porosity and fibre density are engineered to keep the collagen matrix intact while progenitor cells infiltrate, differentiate, and begin depositing Type II collagen and proteoglycans — then allow enzymatic clearance once that provisional matrix has sufficient structural integrity to function without the scaffold beneath it. Too far in either direction and the repair fails; the window sits between those two boundary conditions.

For patients, this has a practical implication that forms part of any realistic clinical conversation. Improvement over the regeneration window is gradual, not immediate. The defect site is not restored at the point of injection — it is being restored across the months that follow, as new ECM accumulates and the scaffold progressively clears. MOCART MRI data from published series reflects this trajectory: scores improve from a mean of 65.3 at four weeks to 81.6 at one year, confirming that tissue maturation is still occurring well past the initial treatment visit. Expecting the process to behave like a pharmaceutical effect — with peak benefit at a single early time-point — would misread the biology entirely.

MRI scores as evidence the replacement is happening

MOCART — Magnetic Resonance Observation of Cartilage Repair Tissue — is a validated scoring system radiologists use to grade how well a cartilage defect has filled and how well the repair tissue integrates with the native cartilage surrounding it. Scores run from 0 to 100; higher figures reflect better defect fill, smoother surface congruence, and stronger border integration.

Published European cohort data show a trajectory that maps closely onto what controlled resorption should produce if it is working as intended. At four weeks post-treatment, mean scores in published series sit around 65 — early repair tissue is present but maturation is still in progress. By one year, the same cohorts report scores rising to above 80, a gain of roughly 16 points sustained across the regeneration window. Final scores in the 81–84 range correspond to greater than 80% defect fill and good integration at the repair-tissue border.

A defect that continues filling across the twelve months in which the scaffold is expected to clear is behaving consistently with the replacement process described in earlier sections — not collapsing as the scaffold disappears, but consolidating. That progressive improvement is the observable footprint of controlled resorption working as designed.

MRI reveals structure: fill volume, surface congruence, border integration. It cannot identify what that tissue is made of at a molecular level. Establishing whether repair tissue is genuinely hyaline-like or fibrocartilaginous in character requires biopsy and histological analysis, and published histological data from human ChondroFiller cases has not yet appeared in the clinical literature. The MOCART data is an indirect but objective signal — the strongest available at this level of evidence.

Hyaline-like repair versus fibrocartilage — why the distinction matters long-term

The distinction matters because not all repair tissue is equal. Microfracture — one of the most widely used cartilage procedures of the past two decades — works by breaching the subchondral bone to recruit bone-marrow-derived cells into the defect. Those cells produce fibrocartilage: a repair tissue that lacks the Type II collagen and proteoglycan density of native hyaline cartilage. Published series suggest fibrocartilage can begin to deteriorate within three to five years, which is why microfracture outcomes often decline at medium-term follow-up.

The entire purpose of ChondroFiller's calibrated resorption window is to avoid that outcome. By remaining structurally intact long enough for infiltrating progenitor cells to differentiate and deposit Type II collagen-rich extracellular matrix — and then clearing — the scaffold gives the regenerating tissue the time it needs to develop the architecture that makes hyaline-like cartilage mechanically resilient. The biology described in earlier sections is in service of this clinical goal.

Functional outcome data from published knee cohorts report approximately 30-point improvements in IKDC scores sustained at three-year follow-up, consistent with repair tissue that holds under load rather than degrading as fibrocartilage tends to do.

The evidence base carries real limits. Published follow-up data do not yet extend beyond three years, and how the scaffold behaves in joints with elevated synovial inflammation — where heightened MMP activity could compress the resorption window — remains an open question.

Patient selection shapes these probabilities. The six-to-twelve-month regeneration window is most likely to complete its full arc — producing the MMP-mediated scaffold clearance and MOCART-confirmed tissue maturation described in earlier sections — when the defect is focal, joint alignment is preserved, and background osteoarthritis is limited. Individual suitability assessment exists precisely to identify that clinical context.

1. [1] Collagen. https://en.wikipedia.org/?curid=6058 https://en.wikipedia.org/?curid=6058
2. [2] Tissue engineering. https://en.wikipedia.org/?curid=307065 https://en.wikipedia.org/?curid=307065